Kringle Pharma (TSE:4884) Loans Receivable: 円0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4884 Kringle Pharma Inc TSE:4884
50 GF Score
Price 円425.00
GF Value 円481.45
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Kringle Pharma Loans Receivable?

Kringle Pharma TSE:4884 -0.93% 50 Loans Receivable is 円0.0 Mil as of Mar. 2026. GuruFocus rates TSE:4884 with a GF Score™ of 50/100 and a GF Value™ of 円481.45 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Kringle Pharma's Loans Receivable for the quarter that ended in Mar. 2026 was 円0.0 Mil.

Kringle Pharma Loans Receivable Historical Data

* Premium members only.

The historical data trend for Kringle Pharma's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kringle Pharma Loans Receivable Chart

Kringle Pharma Annual Data
Trend Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Loans Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Kringle Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4884
50GF Score
Kringle Pharma Inc TSE:4884
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kringle Pharma Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of 円0.0 Mil mean?
Kringle Pharma (TSE:4884) has a Loans Receivable of 円0.0 Mil as of Mar. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Kringle Pharma and its competitors.
Is Kringle Pharma's Loans Receivable too high?
Kringle Pharma's current Loans Receivable is 円0.0 Mil. Overall, Kringle Pharma has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kringle Pharma's Loans Receivable compare to VRTX and REGN?
Kringle Pharma's Loans Receivable of 円0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Kringle Pharma and its competitors. Kringle Pharma's current Loans Receivable is 円0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kringle Pharma stock overvalued right now?
Based on GuruFocus' analysis, Kringle Pharma (TSE:4884) is currently considered Modestly Undervalued. The stock's GF Value™ is 円481.45, compared to a current price of 円425.00 — trading 11.7% below its estimated fair value. The current Loans Receivable is 円0.0 Mil. Kringle Pharma's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Kringle Pharma (TSE:4884), the current Loans Receivable is 円0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kringle Pharma (TSE:4884) Overvalued in 2026?

Based on GuruFocus' analysis, Kringle Pharma stock appears to be undervalued. The current stock price of 円425.00 is trading 11.7% below its estimated GF Value™ of 円481.45. GuruFocus considers Kringle Pharma to be Modestly Undervalued.

Key valuation signals for TSE:4884:

  • Loans Receivable: 円0.0 Mil
  • GF Value™: 円481.45 vs. price of 円425.00 (11.7% below fair value)
  • GF Score™: 50/100 with 5 warning signs

No single metric tells the full story. See the TSE:4884 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kringle Pharma Business Description

Address 7-7-15 Saito asagi, 207 Saito Bio-Incubator, Osaka Prefecture, Ibaraki, JPN, 567-0085
Kringle Pharma Inc is engaged in the research and development of HGF (hepatocyte growth factor) protein as a therapeutic agent for intractable diseases. The Company operates in a single segment, pharmaceutical development.
50GF Score

Get the complete analysis for TSE:4884

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円425.00
Price
円481.45
GF Value